Clinical Trials
18 trialsNCT05405387 2026-05-14
IMPACT
University of Utah
Phase 2 Recruiting
NCT05092451 2026-05-06
Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances
M.D. Anderson Cancer Center
Phase 1/2 Recruiting
NCT07523555 2026-04-13
ADAPT-HEM
Beijing Biotech
Phase 1/2 Recruiting
NCT07509086 2026-04-03
IL-15-Armored CAR-T Therapy in Relapsed or Refractory Multiple Myeloma and Plasma Cell Leukemia
The First Hospital of Jilin University
Phase 2 Recruiting
NCT05870917 2026-03-02
A Study of VRD-based Regimen Combined With CART-ASCT-CART2 Treatment in Patients With Primary Plasma Cell Leukemia
Institute of Hematology & Blood Diseases Hospital, China
Phase 2 Recruiting
NCT06517017 2025-11-28
UltraFrailMM
University of Utah
Phase 2 Recruiting
NCT06730256 2025-10-01
A Study of CT0596 in Relapsed/Refractory Multiple Myeloma and Relapsed/ Refractory Plasma Cell Leukemia
The First Affiliated Hospital of Soochow University
Phase EARLY_PHASE1 Recruiting
NCT07109323 2025-08-07
Autologous Transplantation Combined With BCMA CAR-T in the Treatment of UHR-MM
Institute of Hematology & Blood Diseases Hospital, China
Phase 1/2 Recruiting
NCT07106684 2025-08-06
CAREMM-004
Institute of Hematology & Blood Diseases Hospital, China
Phase 2 Recruiting
NCT05979363 2025-08-03
CAREMM-002
Institute of Hematology & Blood Diseases Hospital, China
Phase 2 Recruiting
NCT06988059 2025-08-01
A Study of CT0596 in Plasma Cell Leukemia
Institute of Hematology & Blood Diseases Hospital, China
Phase EARLY_PHASE1 Recruiting
NCT07085559 2025-07-25
Safety and Efficacy of Metabolically Armed BCMA CAR-T Cells (Meta10-BCMA) in the Treatment of r/r Plasma Cell Neoplasms Clinical Research
Anhui Provincial Hospital
Phase EARLY_PHASE1 Recruiting
NCT05805605 2025-07-01
Allo HSCT Using RIC and PTCy for Hematological Diseases
Masonic Cancer Center, University of Minnesota
Phase 2 Recruiting
NCT03314974 2025-06-24
Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
Masonic Cancer Center, University of Minnesota
Phase 2 Recruiting
NCT05219721 2025-06-11
A Study of CAR-GPRC5D in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia
Tongji Hospital
Phase 1 Recruiting
NCT05759793 2025-05-20
A Study of CAR-GPRC5D in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia
Nanjing IASO Biotechnology Co., Ltd.
Phase 1 Recruiting
NCT06718270 2024-12-12
a Study of CT0596 in Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Plasma Cell Leukemia
Shanghai Changzheng Hospital
Phase EARLY_PHASE1 Recruiting
NCT06045091 2023-09-21
To Evaluate the Safety and Efficacy of Human BCMA Targeted CAR-NK Cells Injection for Subjects With R/R MM or PCL
Hrain Biotechnology Co., Ltd.
Phase EARLY_PHASE1 Recruiting